SAN FRANCISCO ( TheStreet) -- Welcome to the J.P. Morgan Biotech Confab Live Chat.
I'm here to offer my take on the first day of the biotech sector's largest and most important investor conference. And of course, I'm happy to answer your biotech stock investing questions.
This year's J.P. Morgan conference should be renamed the Hepatitis C Hoedown for the buzz being generated about Bristol-Myers Squibb's (BMY) $2.5 billion acquisition of Inhibitex (INHX) and the resulting speculative mania that is gripping Idenix Pharmaceuticals (IDIX) and Achillion Pharmaceuticals (ACHN). Both stocks are seen as potential takeover targets, too, but how likely is that or is it just wishful thinking?I spent my day listening to presentations by Celgene (CELG - Get Report), Onyx Pharmaceuticals (ONXX), Amarin (AMRN - Get Report), Vivus, (VVUS - Get Report) and Dendreon (DNDN). --Written by Adam Feuerstein in San Francisco.
>To contact the writer of this article, click here: Adam Feuerstein. >To follow the writer on Twitter, go to http://twitter.com/adamfeuerstein. >To submit a news tip, send an email to: firstname.lastname@example.org. Follow TheStreet on Twitter and become a fan on Facebook.